Last reviewed · How we verify
Secondary physiologic amenorrhea — Treatment Landscape & Competitive Intelligence
5 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aygestin | NORETHINDRONE ACETATE | Duramed Res | Estrogen [EPC] | Progesterone receptor | 1973-01-01 | |
| Micronor | norethisterone | Johnson & Johnson | Progestin | GnRH receptors | 1962-01-01 | |
| Endometrin | progesterone | Ferring | Progesterone [EPC] | Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 | ||
| Progesteron | Progesteron | Minia University | Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 | |||
| Depo-Provera | medroxyprogesterone | Pfizer | Progestin | Progesterone receptor | 1959-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Duramed Res · 1 drug in Secondary physiologic amenorrhea
- Ferring · 1 drug in Secondary physiologic amenorrhea
- Johnson & Johnson · 1 drug in Secondary physiologic amenorrhea
- Minia University · 1 drug in Secondary physiologic amenorrhea
- Pfizer · 1 drug in Secondary physiologic amenorrhea
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Secondary physiologic amenorrhea:
- Secondary physiologic amenorrhea treatment updates — RSS
- Secondary physiologic amenorrhea treatment updates — Atom
- Secondary physiologic amenorrhea treatment updates — JSON
Cite this brief
Drug Landscape (2026). Secondary physiologic amenorrhea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-physiologic-amenorrhea. Accessed 2026-06-10.
Related
- Secondary physiologic amenorrhea full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing